摘要 |
The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies. |
申请人 |
SYMPHOGEN A/S |
发明人 |
LANTTO, JOHAN;ANDERSEN, KIM VILBOUR;ANDERSEN, PETER SEJR;STRANDH, MAGNUS;KOEFOED, KLAUS;NIELSEN, LARS SOGAARD;PEDERSEN, MIKKEL WANDAHL;JACOBSEN, HELLE;KRAGH, MICHAEL;KJAER, IDA;POULSEN, THOMAS TUXEN |